

Fabiana Conciatori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6501136/publications.pdf>

Version: 2024-02-01

30
papers

1,786
citations

361296

20
h-index

477173

29
g-index

30
all docs

30
docs citations

30
times ranked

3577
citing authors

#	ARTICLE	IF	CITATIONS
1	Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3837.	1.8	22
2	Exploring CT Texture Parameters as Predictive and Response Imaging Biomarkers of Survival in Patients With Metastatic Melanoma Treated With PD-1 Inhibitor Nivolumab: A Pilot Study Using a Delta-Radiomics Approach. <i>Frontiers in Oncology</i> , 2021, 11, 704607.	1.3	16
3	Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. <i>Cancers</i> , 2020, 12, 2870.	1.7	64
4	Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8841.	1.8	28
5	AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8419.	1.8	14
6	PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5337.	1.8	26
7	BRAF status modulates Interleukin-8 expression through a CHOP-dependent mechanism in colorectal cancer. <i>Communications Biology</i> , 2020, 3, 546.	2.0	8
8	From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. <i>Cells</i> , 2020, 9, 309.	1.8	23
9	Translational Landscape of mTOR Signaling in Integrating Cues Between Cancer and Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1223, 69-80.	0.8	5
10	JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 28.	3.5	24
11	Advances in Tumor-Stroma Interactions: Emerging Role of Cytokine Network in Colorectal and Pancreatic Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-12.	0.6	20
12	The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response. <i>Cancers</i> , 2019, 11, 629.	1.7	30
13	PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?. <i>Cancers</i> , 2019, 11, 435.	1.7	86
14	Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. <i>Cancers</i> , 2019, 11, 1661.	1.7	48
15	Colorectal cancer stem cells properties and features: evidence of interleukin-8 involvement. , 2019, 2, 968-979.		2
16	mTOR Cross-Talk in Cancer and Potential for Combination Therapy. <i>Cancers</i> , 2018, 10, 23.	1.7	108
17	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 140.	3.5	27
18	Role of mTOR Signaling in Tumor Microenvironment: An Overview. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2453.	1.8	109

#	ARTICLE	IF	CITATIONS
19	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. <i>Scientific Reports</i> , 2017, 7, 43013.	1.6	44
20	Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer. <i>Annals of Oncology</i> , 2017, 28, 2896-2898.	0.6	13
21	Emerging Insight into MAPK Inhibitors and Immunotherapy in Colorectal Cancer. <i>Current Medicinal Chemistry</i> , 2017, 24, 1383-1402.	1.2	23
22	PTEN: Multiple Functions in Human Malignant Tumors. <i>Frontiers in Oncology</i> , 2015, 5, 24.	1.3	356
23	PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. <i>Advances in Biological Regulation</i> , 2014, 56, 66-80.	1.4	77
24	Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC. <i>Current Pharmaceutical Design</i> , 2014, 20, 3944-3957.	0.9	55
25	Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. <i>Journal of Molecular Medicine</i> , 2012, 90, 1133-1144.	1.7	35
26	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. <i>Journal of Molecular Medicine</i> , 2012, 90, 667-679.	1.7	54
27	Targeting targeted agents: open issues for clinical trial design. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 66.	3.5	18
28	Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations. <i>Neoplasia</i> , 2009, 11, 720-W6.	2.3	87
29	Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus. <i>Cancer Research</i> , 2006, 66, 5549-5554.	0.4	314
30	Trastuzumab Down-Regulates Bcl-2 Expression and Potentiates Apoptosis Induction by Bcl-2/Bcl-XL Bispecific Antisense Oligonucleotides in HER-2Gene"Amplified Breast Cancer Cells. <i>Clinical Cancer Research</i> , 2004, 10, 7747-7756.	3.2	50